HIPK2 is a eukaryotic Serine-Threonine kinase that controls cellular proliferation and survival in response to exogenous signals. Here, we show that the human transcription factor ZBTB4 is a new target of HIPK2. The two proteins interact in vitro, colocalize and associate in vivo, and HIPK2 phosphorylates several conserved residues of ZBTB4. Overexpressing HIPK2 causes the degradation of ZBTB4, whereas overexpressing a kinasedeficient mutant of HIPK2 has no effect. The chemical activation of HIPK2 also decreases the amount of ZBTB4 in cells. Conversely, the inhibition of HIPK2 by drugs or by RNA interference causes a large increase in ZBTB4 levels. This negative regulation of ZBTB4 by HIPK2 occurs under normal conditions of cell growth. In addition, the degradation is increased by DNA damage. These findings have two consequences. First, we have recently shown that ZBTB4 inhibits the transcription of p21. Therefore, the activation of p21 by HIPK2 is twopronged: stimulation of the activator p53, and simultaneous repression of the inhibitor ZBTB4. Second, ZBTB4 is also known to bind methylated DNA and repress methylated sequences. Consequently, our findings raise the possibility that HIPK2 might influence the epigenetic regulation of gene expression at loci that remain to be identified.
Introduction
The Homeodomain-interacting protein kinase 2 (HIPK2) is a nuclear kinase that regulates the activity of several transcription factors (Rinaldo et al., 2007b) . One of them is p53, which HIPK2 phosphorylates on serine 46 in response to pro-apoptotic stimuli (D'Orazi et al., 2002; Hofmann et al., 2002) . Phosphorylated p53 then activates specific target genes, such as p53AIP1, to induce cell death (Oda et al., 2000) . If the damage is not severe enough to trigger apoptosis, HIPK2 permits the induction of p21, which allows cells to stop their cycle while repairs take place (Di Stefano et al., 2005) . The deletion of HIPK2 in mice is pleiotropic, but supports a role of the kinase in cell survival (Isono et al., 2006; Wei et al., 2007) . In addition to regulating transcription factors, HIPK2 binds, phosphorylates and regulates the activity of the chromatin protein HMGA1 (Pierantoni et al., 2001 (Pierantoni et al., , 2007 Zhang and Wang, 2007) , and it also acts on the Polycomb group protein Pc2 . The regulation of HMGA1 and Pc2 suggests that HIPK2 may also act at the level of epigenetic control.
ZBTB4 is a mammalian transcription factor that we initially isolated because of its ability to bind methylated DNA in vitro and in vivo (Filion et al., 2006a,b) . ZBTB4 belongs to a family of proteins with Zinc fingers and a BTB domain (Kelly and Daniel, 2006; Perez-Torrado et al., 2006) . Similar to other proteins in this family, such as BCL-6 (Phan et al., 2005) , ZBTB4 can also be indirectly recruited to the genome by contacting a DNAbound protein. Indeed, we and others have recently shown that MIZ-1 can tether ZBTB4 to the promoter of p21 (Weber et al., 2008) .
ZBTB4 plays an important role at the p21 promoter (Weber et al., 2008) . It represses the transcription of p21, which impedes cell-cycle arrest and causes the DNA damage response to shift away from repair and toward apoptosis. Accordingly, neuroblastoma cells with decreased ZBTB4 are less prone to apoptosis after treatment with chemotherapeutics. This probably explains why many high-grade neuroblastomas have ZBTB4 expression levels that are much lower than low-grade tumors or control tissue (Weber et al., 2008) .
As ZBTB4 regulates p21 expression and probably also methylated loci, we sought to study its regulation. Our search for ZBTB4 interactors yielded HIPK2. Here, we describe the interaction between the two proteins and its consequences. These data give us further detail into the mechanisms by which HIPK2 acts to regulate the expression of p21. In addition, they strengthen the hypothesis that HIPK2 might influence epigenetic processes.
Results

Identification of HIPK2 as a ZBTB4 interactor
The potential role of ZBTB4 in cancer led us to seek its regulators, and for this we used a two-hybrid approach. We screened a library of mouse brain cDNAs, and obtained a fragment of the protein HIPK2 (Figure 1a) . The interaction domain was located in the C-terminus of ZBTB4 (Figure 1b) . In a pull-down assay (Figure 1c) , we observed interaction between ZBTB4 and a C-terminal fragment of HIPK2.
We conclude that a direct interaction with ZBTB4 is mediated by a region of HIPK2 overlapping the PEST domain.
Interaction between HIPK2 and ZBTB4 in mammalian cells We then tested whether HIPK2 and ZBTB4 coimmunoprecipitate ( Figure 2a) . We found that an HIPK2 immunoprecipitate contains significant amounts of ZBTB4. Next, we asked whether the two proteins colocalize in cells (Figure 2b ). For this, we tagged proteins with the green fluorescent protein (GFP) or the red fluorescent protein (RFP). As reported, we found GFP-HIPK2 in nuclear foci (Rinaldo et al., 2008) , and ZBTB4-RFP was diffuse nuclear (Filion et al., 2006b) . When GFP-HIPK2 and RFP-ZBTB4 were cotransfected, there was a strong colocalization. Also, HIPK2 relocalized to a mostly diffuse nuclear pattern that resembled the ZBTB4 distribution. Some small HIPK2 foci remained intact and did not overlap with ZBTB4. A kinase-inactive version of HIPK2 (mutant K221A, Figure 2c ) was nuclear but not recruited into foci, as published (Moller et al., 2003) . This mutant protein broadly colocalized with ZBTB4. Finally, we transfected a point mutant of ZBTB4 that is defective for DNA binding (Mutant RR, described in Supplementary Figure 5 ). This protein was nuclear and, unlike wildtype ZBTB4, found in foci. Upon coexpression of HIPK2, the colocalization was extensive and in a pattern similar to HIPK2 foci (Figure 2d) .
Collectively, these data suggest that overexpressed ZBTB4 can titrate HIPK2 away from its foci and onto the genome. Conversely, a mutant form of ZBTB4 that does not bind DNA is incorporated into HIPK2 foci. In addition, these results further establish the interaction between HIPK2 and ZBTB4 in vivo.
HIPK2 downregulates ZBTB4 at the protein level To try and understand the relationship between ZBTB4 and HIPK2, we first used cells stably depleted for HIPK2. These cells are derived from the colon cancer cell line RKO, and stably express a short hairpin RNA directed against HIPK2 (Di Stefano et al., 2004) . By western blotting, we found a fourfold increase in the ZBTB4 signal in cells depleted of HIPK2 relative to control cells (Figure 3a ). This effect was seen with two independent antibodies directed against different regions of ZBTB4. Acute depletion of HIPK2 in RKO cells by small interfering RNAs (siRNAs) also increased ZBTB4 abundance (not shown). The effect of siRNAs was also seen in U2OS, an osteosarcoma cell line (see Figure 3c) , and in the breast cancer cell line MCF7 (see following sections). We conclude, therefore, that ZBTB4 is more abundant in cells depleted of HIPK2.
By quantitative RT-PCR, we found that the level of ZBTB4 mRNA was unaffected by the depletion of HIPK2 in RKO cells (Figure 3b ) or in U2OS cells (Figure 3d ). The upregulation of ZBTB4 on HIPK2 depletion therefore occurs at the post-transcriptional level.
To further characterize the effect of HIPK2 knockdown, we carried out immunofluorescence experiments. The endogenous ZBTB4 protein was nuclear and excluded from nucleoli (Figure 3e ), in agreement with results using fluorescent proteins (Figure 2 ). After transfection of siRNAs against HIPK2, the ZBTB4 signal was increased ( Figure 3e , bottom row).
To quantify this phenomenon, we took advantage of the following fact. The amount of ZBTB4 is lowest in mitotic cells: in the control culture, only 19.6 % of mitotic cells had a detectable ZBTB4 signal by immunofluorescence ( Figure 3e , top row). By contrast, after the transfection of HIPK2-interfering siRNAs, a ZBTB4 signal became detectable in 76.5 % of mitotic cells (Figure 3e , bottom row). Although the upregulation of ZBTB4 after HIPK2 depletion is easiest to score in mitotic cells, it seems not to be restricted to this particular phase of the cell cycle. Indeed, most of the cells observed had a stronger ZBTB4 signal on HIPK2 inhibition than in the control condition (Figure 3e , compare top and bottom row).
From this set of experiments, we conclude that ZBTB4 is upregulated post-transcriptionally when HIPK2 is depleted. In other words, the presence of HIPK2 downregulates ZBTB4 at the protein level.
Downregulation of ZBTB4 is dependent on HIPK2 kinase activity We next assessed the consequence of HIPK2 overexpression on endogenous ZBTB4 by carrying out transfection of MCF7 cells. The level of endogenous ZBTB4 (Figure 4a ) was generally low in HIPK2-transfected cells. The kinase-inactive mutant of HIPK2, by contrast, had no effect on the level or distribution of the ZBTB4 signal (Figure 4a , bottom row).
Two additional experiments show that the activity of HIPK2 regulates the amount of ZBTB4. First, we used the cell line MCF7, in which the level of HIPK2 is modest (Hofmann et al., 2002) , and stimulated its activity by using Roscovitine, a known HIPK2 activator (Wesierska-Gadek et al., 2007) . The induction of p21, which is triggered by HIPK2 under these conditions (Wesierska-Gadek et al., 2007) , served as a positive control of Roscovitine effect ( Figure 4b ). The Roscovitine treatment caused a decrease of ZBTB4 abundance ( Figure 4b ). For the converse experiment, we used U2OS cells, in which the HIPK2 level is high (Hofmann et al., 2002) , and diminished this activity with the known inhibitor SB203580 . In this case, we observed increased ZBTB4 abundance ( Figure 4c ). As mentioned earlier, the upregulation of ZBTB4 was easiest to quantify in mitotic cells, but seemed to occur in all phases of the cell cycle.
From these experiments, we conclude that the kinase activity of HIPK2 controls, directly or indirectly, the ZBTB4 protein level.
HIPK2 phosphorylates three conserved threonines in ZBTB4 Next, we asked whether HIPK2 can directly phosphorylate ZBTB4. We focused on the C-terminal fraction of ZBTB4, which interacts with HIPK2 ( Figure 1b) . By in vitro kinase assays, we found that GST-Cter was phosphorylated by HIPK2 ( Figure 5a ).
HIPK2 phosphorylates P-S/T and S/T-P sites (ML Schmitz, unpublished), so we concentrated on three such sites found in the C-terminus that are highly conserved between mammals (Figure 5b ). Mutating all three positions generated a construct, GST-ZBTB4 C-ter TM (Triple Mutant), which is no longer phosphorylated by HIPK2 (Figure 5a ). By combining single and double mutations, we found that all three positions can be phosphorylated by HIPK2 (Figure 5c ).
Our conclusion then is that HIPK2 can phosphorylate threonines 795, 797 and 983 of human ZBTB4.
The level of ZBTB4 protein is decreased after DNA damage HIPK2 is activated after DNA damage (Calzado et al., 2007) . This prompted us to test whether ZBTB4 might be affected by DNA damage. We again used the MCF7 breast cancer cell line in which both ZBTB4 and HIPK2 are present endogenously, and the amount of kinase is relatively modest (Hofmann et al., 2002) . We exposed the cells to increasing doses of g-rays from a Cesium source, and the induction of p21 was used as a control to Treatment of the cells with g-rays caused a decrease in ZBTB4 abundance (Figure 6a) . A time-course experiment showed that the depletion was visible 24 h after treatment, and persisted for at least 48 h (Figure 6b ). The kinetics of ZBTB4 decrease mirrored the induction of p21, consistent with the idea that ZBTB4 represses the expression of p21 (Weber et al., 2008) . Irradiation with UV is another event that activates HIPK2 (Zhang et al., 2003) . In that case as well, we saw a decrease of ZBTB4 after DNA damage (Supplementary Figure 3) .
To test whether HIPK2 is involved in the regulation of ZBTB4 by DNA damage, we transfected HIPK2 with siRNA into MCF7 cells and then treated it with g-rays (Figure 6c ). We verified that the siRNA treatment decreased the abundance of HIPK2 mRNA and had no effect on the ZBTB4 mRNA (Figure 6d ). Another readout of HIPK2 inhibition shows that the induction of p21 was lessened (Figure 6c ). We found again that ZBTB4 was decreased after treatment with g-rays, but that this decrease was weak or absent after the knockdown of HIPK2 (Figure 6c ). These results show that HIPK2 is involved in the degradation of ZBTB4 induced by DNA damage.
Discussion
The interaction between ZBTB4 and HIPK2: possible consequences for the kinase We report an interaction between the human transcription factor ZBTB4 and the protein kinase HIPK2 (Figures 1 and 2 ). The region of HIPK2 that interacts with ZBTB4 contains the PEST domain, the adjacent autoinhibitory region (Rui et al., 2004 ) and a destabilization motif (Rinaldo et al., 2007a) . This finding has four consequences: First, this portion of HIPK2 also interacts with other proteins, including p53 (Rinaldo et al., 2007b) . This suggests a competition between the different proteins for binding to HIPK2. Second, ZBTB4 binds a region close to a domain of HIPK2 that inhibits its kinase activity. This raises the possibility that interaction with ZBTB4 could modulate (positively or negatively) the auto-inhibition and influence the signaling outcome. Third, contact with ZBTB4 may also mask, or make more accessible, the destabilization domain of HIPK2 and modify its stability. Fourth, this region of HIPK2 is conserved in the paralogs HIPK1 and HIPK3 (Rinaldo et al., 2008) . It is possible that these kinases too interact with ZBTB4 and affect its function. This seems especially likely in the case of HIPK1, which is functionally redundant with HIPK2 (Isono et al., 2006) . Further investigations will address these possibilities.
HIPK2, ZBTB4 and the induction of p21 p53 orchestrates two kinds of response after genotoxic damage. If the damage is severe, it will induce a battery of pro-apoptotic genes. By contrast, if the damage is compatible with survival, p53 induces DNA repair. It also activates p21, which arrests the cell cycle while Figure 2 HIPK2 and ZBTB4 interact in vivo. (a) ZBTB4 and HIPK2 co-immunoprecipitate. Endogenous HIPK2 was immunoprecipitated from human U2OS cells using a specific rabbit antiserum. A control immunoprecipitation was carried out with non-specific antibodies. The presence of HIPK2 and ZBTB4 in the input (5% of the material used for precipitation), and in the precipitated fractions, was examined by western blotting with antibodies against the respective endogenous proteins. The bands of lower molecular weight observed with the anti-HIPK2 antibody (asterisk) are processed forms . (b) HIPK2 and ZBTB4 colocalize in the nucleus. Human MCF7 cells were transfected with the indicated combinations of expression constructs for GFP, RFP, GFP-HIPK2 or RFP-ZBTB4. The nucleus was counterstained with DAPI. (c) The kinase activity of HIPK2 is not required for colocalization with ZBTB4. HIPK2 K221A is a catalytically inactive point mutant. (d) DNA binding is not required for ZBTB4 to bind HIPK2. ZBTB4 RR has two point mutations and does not bind DNA.
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D Yamada et al repair is taking place (Bunz et al., 1998) . HIPK2 is absolutely required for this induction, even though it does not phosphorylate p53 in this case (Di Stefano et al., 2005) . We have recently shown that ZBTB4 represses the transcription of p21, and opposes the cell-cycle arrest response in damaged cells, directing them toward apoptosis instead (Weber et al., 2008) . This may be a reason why the expression of ZBTB4 is counter-selected in tumors (M Caly et al., in prep.; Weber et al., 2008) . The role of HIPK2 in the induction of p21 may be to cause the degradation of ZBTB4, lifting the repression and permitting a shift to a permissive status of the p21 promoter, which can then be transactivated by p53.
In the early phases of apoptosis, HIPK2 is processed by caspases (Gresko et al., 2006) . As this clipping Total protein extracts were prepared from RKO cells stably transfected with an shRNA construct directed against HIPK2 (shHIPK2), or with a control plasmid (shCont.). The level of ZBTB4 protein was monitored using two different polyclonal antibodies (#98 and #120). GAPDH was used as a loading control. Serial two-fold dilutions of the extracts were used in western blotting to verify the linearity of the signal. (b) HIPK2 depletion does not affect the level of ZBTB4 mRNA. Total RNA was extracted from the cells used in panel A. The level of HIPK2 and ZBTB4 mRNA in each cell line was then measured by quantitative RT-PCR and normalized relative to b-Actin mRNA. The level of each mRNA was set as 100% in the control cell line. (c) Increased ZBTB4 protein level after acute depletion of HIPK2. Total protein was extracted from U2OS cells transfected with siRNA against HIPK2 (siHIPK2) or control siRNA (siCont.). Western blotting was carried out as in panel A. (d) Acute HIPK2 depletion does not affect the level of ZBTB4 mRNA. Total RNA was extracted from the transfected U2OS cells described in panel C. The different mRNA levels were measured as in B. (e) Quantification of the effect at the cellular level. MCF7 cells were transfected with siRNA directed against HIPK2 (siHIPK2), or negative control siRNA (siCont.). The cells were then subjected to immunofluorescence with an antibody directed against ZBTB4 (#120, green signal), and the nuclei counterstained with DAPI. A representative field of cells is shown. In control cells, the ZBTB4 signal in mitotic cells (white arrow) is low or undetectable. In cells depleted of HIPK2, many mitotic cells have a detectable ZBTB4 signal. The percentages of labeled cells were compared by Fischer's exact test. Nomarski imaging was used to ensure that only morphologically normal cells were included in the scoring. Figure 4 The kinase activity of HIPK2 negatively regulates the ZBTB4 protein level. (a) HIPK2 overexpression decreases ZBTB4 protein abundance. Human MCF7 cells were transfected with GFP (Control), GFP-HIPK2 (HIPK2 WT) or a kinase-deficient mutant (HIPK2 K221A). Cells were then subjected to immunofluorescence with an antibody directed against ZBTB4 (#120, red signal) and the nuclei counterstained with DAPI. The arrowhead shows GFP-positive cells. The percentages of labeled cells were compared by Fischer's exact test. (b) The activation of HIPK2 by Roscovitine (ROSC) leads to a decrease of the ZBTB4 protein level. MCF7 cells were incubated with Roscovitine (ROSC), the corresponding solvent DMSO (solv.), or left untreated (unt.). The induction of p21 is a positive control of Roscovitine action. Western blotting was carried out as in Figure 3 . (c) The chemical inhibition of HIPK2 by SB203580 leads to an increase of ZBTB4 abundance. After treatment of U2OS cells, ZBTB4 becomes detectable in many mitotic cells, from which it is absent in control conditions (DMSO is the vehicle control). The percentages of labeled cells were compared by Fischer's exact test. Nomarski imaging was used to ensure that only morphologically normal cells were included in the scoring.
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D Yamada et al removes the ZBTB4-interaction domain almost entirely, we speculate that caspase-activated HIPK2 no longer interacts with ZBTB4. This would be consistent with the idea that HIPK2 degrades ZBTB4 under conditions of mild damage.
The degradation of ZBTB4 by HIPK2: when, where and why?
The removal of HIPK2 greatly increases the amount of ZBTB4 protein, whereas the overexpression of HIPK2 decreases the amount of ZBTB4 (Figures 3 and 4) . This could be a direct effect, linked to the phosphorylation of ZBTB4 by HIPK2, for the following reasons: First, the proteins interact directly (Figure 2) . Second, HIPK2 can phosphorylate ZBTB4 in vitro ( Figure 5 ). The target residues are evolutionarily conserved, an indication of their potential significance. Third, a kinase-inactive mutant of HIPK2 has no effect on ZBTB4 (Figure 4 ). By analogy with the action of HIPK2 on CtBP (Zhang et al., 2005) , phosphorylation by HIPK2 might mark ZBTB4 for ubiquitination and degradation by the proteasome. We note that GFP-ZBTB4 was not significantly degraded by HIPK2 (Figure 2b ). This unexpected observation may be due to interference from the epitope tags. Alternatively, as GFP-ZBTB4 is expressed to very high levels, it may reflect the saturation of an unknown limiting factor that is required for ZBTB4 to be degraded in response to HIPK2 activation. The degradation of ZBTB4 by HIPK2 may have a role in at least four situations: normal cellular growth, DNA damage, cancer and signaling by the Wnt pathway.
In normal conditions, ZBTB4 is very tightly bound to chromatin: it is not removed from the nucleus by detergent extraction; its mobility in FRAP experiments is very low and the pool of protein that is nuclear soluble is low (Defossez, unpublished) . By contrast, in interphase, HIPK2 resides mostly in nuclear foci that partially correspond to PML bodies. It seems that the proteins can only meet when ZBTB4 is removed from DNA, when HIPK2 is released from its foci, or both. In normally growing cells, HIPK2 may serve to degrade all the ZBTB4 molecules that are not DNA-bound, which would account for the lack of a soluble pool of the protein, and could explain the total colocalization observed between HIPK2 and a mutant form of ZBTB4 that does not bind DNA (Figure 2 ). Before and during mitosis, the reorganization of PML bodies (Engelhardt HIPK2 is also required for the degradation of ZBTB4 after DNA damage. It is possible that, in this situation, ZBTB4 is released from DNA and diffuses into contact with HIPK2. This is the case for p53, which is recruited into HIPK2 foci after DNA damage (D'Orazi et al., 2002; Hofmann et al., 2002) .
HIPK2 is overexpressed in some brain tumors (Deshmukh et al., 2008) . It would be interesting to determine whether ZBTB4 is downregulated at the protein level in these same tumors, and whether this contributes to their malignancy by a mechanism involving p21. Conversely, ZBTB4 is underexpressed in breast tumors, prostate tumors and neuroblastoma. This is due, at least in part, to a downregulation at the transcriptional level (Weber et al., 2008) . However, the low abundance of ZBTB4 protein that we have observed in breast tumors (M. Caly et al., in prep.) may also depend on post-translational effects, including degradation of the protein by HIPK2 and/or other regulators.
Finally, HIPK2 relays both DNA damage response and Wnt signaling (Kanduri et al., 2002; Lee et al., 2009) . Kaiso, a close paralog of ZBTB4 in mammals, is itself regulated by Wnt signals (van Roy and McCrea, 2005) . It is possible that ZBTB4, similar to Kaiso, is a target of the Wnt pathway in a process involving HIPK2.
Is HIPK2 an epigenetic regulator? ZBTB4 binds methylated DNA and represses the transcription of methylated reporter genes (Filion et al., 2006b) . Very little is known about the posttranslational modifications that regulate the activity of methyl-binding transcription factors (Clouaire and Stancheva, 2008) . To our knowledge, ours is the first example of a kinase regulating the amount of a mammalian methyl-binding protein.
Earlier reports have shown that HIPK2 regulates the protein Pc2, a component of the Polycomb complex PRC1 , and also that it acts on the chromosomal protein HMGA1 (Pierantoni et al., 2007) . These findings, and our own, suggest that HIPK2 may be a global epigenetic regulator of chromatin structure. An interesting possibility would be that HIPK2 acts on the organization of chromatin to facilitate DNA repair (Supplementary Figure 4) . Abnormal DNA repair, or abnormal epigenetic maintenance, could both contribute to the tumorigenic potential of cells lacking HIPK2 (Li et al., 2007; Wei et al., 2007) .
Materials and methods
Two-hybrid screening
Full-length human ZBTB4 was cloned into pGBDU-C(1) (James et al., 1996) , and used to screen a library of mouse brain cDNAs. Out of 5 Â 10 6 transformants, we found 268 interactors after secondary screens. Seven clones contained the same partial HIPK2 cDNA.
in vitro pull-down assay The plasmids encoding various regions of human HIPK2 fused to GST were a kind gift of Nelson Dusetti (Tomasini et al., 2003) . They were used to transform BL21 bacteria and produce the corresponding recombinant proteins. Radiolabeled ZBTB4 was produced by in vitro transcription and translation of plasmid pSG5-ZBTB4 using rabbit reticulocyte lysate (TNT, Promega, Madison, WI, USA). The pulldown was then performed as described earlier (Defossez et al., 2005) .
Immunoprecipitation
For immunoprecipitation of HIPK2, cellular extracts were prepared using a specific protocol that efficiently releases this protein (Pierantoni et al., 2001) . Endogenous HIPK2 was detected by western blot using a rabbit polyclonal serum (Moller et al., 2003) .
Cell culture and transfection MCF7 and U2OS cells were cultured in DMEM supplemented with 10% heat-inactivated fetal calf serum (FCS). RKO pSuper or RKO pSuper-shHipk2 cells (kindly given by Gabriella D'Orazi) were cultured in RPMI-1640 supplemented with 10% heat-inactivated FCS and 2 mg/ml puromycin. All cells were cultured at 37 1C in a humidified 5% CO 2 atmosphere.
Transfection was carried out with Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Twenty-four hours after transfection, the cells were fixed for 10 min in 2% paraformaldehyde, permeabilized with 0.5% Triton X-100 at 4 1C, and the nucleus was stained with 4 0 -6-diamidino-2-phenylindole (DAPI).
Protein extraction and western blotting Cells were washed with PBS, lysed in cold buffer (50 mM TrisHCl, pH7.5, 150 mM NaCl, 1% Nonidet P-40) and sonicated in a Bioruptor (Cosmo Bio, Tokyo, Japan). Cell lysates were centrifuged to remove cell debris. The following antibodies were used for western blotting under the conditions recommended by the manufacturers: anti-p21 (Cell Signaling Technologies 2946, Beverly, MA, USA), anti-Flag M2 (Sigma F3165, St Louis, MO, USA), anti-tubulin (Abcam ab7291, Cambridge, UK), anti-GAPDH (Abcam ab9485).
ZBTB4 was detected using PAD#98, the fourth bleed of a rabbit polyclonal serum raised against residues 1-125 of the human protein (Filion et al., 2006b ). The dilution was 1/3000. We also generated for this study an independent polyclonal antiserum, PAD#120, directed against residues 797-970 of ZBTB4. The specificity of the antibody in western blotting and immunofluorescence was validated by experiments shown in Supplementary Figures 1 and 2 . The dilution of PAD#120 used in western blotting was 1/3000.
RNA extraction and cDNA synthesis Total RNA was isolated using Trizol (Invitrogen). cDNAs were synthesized with SuperScript III (Invitrogen) using oligo (dT) primers.
Quantitative real-time RT-PCR
The mRNA expression levels were quantified by real-time PCR on a LightCycler instrument (Roche, Indianapolis, IN, USA) with SYBR Green PCR Master Mix (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Primers were designed using Primer3 software (http://frodo. wi.mit.edu/cgi-bin/primer3/prime3_www.cgi). Sequences for primers are shown in Supplementary 2), and each standard curve was developed using the LightCycler Software (Roche). The quantification was carried out using the Fit-points method, and the amount of each gene was calculated relative to the housekeeping gene -actin. The specificities of the RT-PCR products were monitored by melting curve analysis.
Gamma-ray irradiation
Cells were irradiated at room temperature using a
137
Cs g-ray source, IBL637 (CisBio international, Bagnols-sur-Ce`ze, France), with a dose rate of 3.82 Gy/min. After irradiation, the medium was immediately changed and the cells were further incubated for the durations indicated in the Figures.
Small interfering RNA (siRNA)
The small interfering RNA targeting human HIPK2 had the following sequence: 5 0 -UUAGUAUGGAGACUUCGGAU UGGC-3 0 (Stealth Select RNAi, Invitrogen). The duplexes were introduced into cells by reverse transfection (Ovcharenko et al., 2005) .
in vitro kinase assay GST-fused protein (0.1 mg) was incubated for 10 min at 30 1C with recombinant HIPK2 (Upstate Biochemicals, Lake Placid, NY, USA) and radioactive g-ATP in reaction buffer (8 mM MOPS, pH7.0, 0.2 mM EDTA).
Plasmids
All the plasmids used in this study are listed in Supplementary  Table 2 . The RFP-HIPK2 construct was generated by extracting the mouse HIPK2 cDNA from a plasmid kindly given by Sylvia Soddu (D'Orazi et al., 2002) . Other construction details are available on request.
